SCHEDULE: Vanguard Discloses 5.21% Stake in Alkermes PLC

Vanguard Capital Management has reported beneficial ownership of 8,676,888 shares, representing 5.21% of Alkermes PLC's common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 8,676,888 shares of Alkermes PLC common stock.
• This holding represents 5.21% of the total class of securities.
• The filing indicates sole voting power for 1,249,491 shares and sole dispositive power for 8,676,888 shares.
• The reporting date for this ownership stake is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing institutional ownership stake rather than new strategic developments or financial performance.

Positives

• Vanguard's significant stake suggests confidence in Alkermes PLC's long-term prospects.
• The filing confirms a substantial institutional investor's commitment to the company.

Future Outlook

This filing does not contain forward-looking statements or guidance from Alkermes PLC. It solely reports Vanguard's ownership stake.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major institutional investor like Vanguard often signals a passive investment strategy, but a stake exceeding 5% can still be a significant indicator of market sentiment towards Alkermes PLC within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's continued or established position, which can be viewed positively for stability and market interest.
• Management: The presence of a large institutional holder like Vanguard may influence strategic decisions and corporate governance practices.

Key Dates

Keywords

Alkermes PLC, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing